295 related articles for article (PubMed ID: 6300162)
61. Partial deficiency of adrenal 11-hydroxylase. A possible cause of primary hypertension.
de Simone G; Tommaselli AP; Rossi R; Valentino R; Lauria R; Scopacasa F; Lombardi G
Hypertension; 1985; 7(2):204-10. PubMed ID: 2984117
[TBL] [Abstract][Full Text] [Related]
62. [The effect of metoclopramide and dopamine on mineralocorticoid secretion--in vivo and in vitro studies].
Ojima M; Itoh N; Kusano Y; Yaginuma K; Fukuchi S
Nihon Naibunpi Gakkai Zasshi; 1986 Mar; 62(3):197-207. PubMed ID: 3709883
[TBL] [Abstract][Full Text] [Related]
63. Suppression of adrenal mineralocorticoid production in prehypertensive young adult men.
Guthrie GP; Kotchen TA; Kotchen JM
J Clin Endocrinol Metab; 1983 Jan; 56(1):87-92. PubMed ID: 6292257
[TBL] [Abstract][Full Text] [Related]
64. Mineralocorticoid hypertension in childhood.
New MI; Levine LS
Mayo Clin Proc; 1977 May; 52(5):323-8. PubMed ID: 323586
[TBL] [Abstract][Full Text] [Related]
65. Unresponsiveness of plasma mineralocorticoids to angiotensin II in diabetic patients with asymptomatic normoreninemic hypoaldosteronism.
Kigoshi T; Morimoto S; Uchida K; Hosojima H; Yamamoto I; Imaizumi N; Azukizawa S
J Lab Clin Med; 1985 Feb; 105(2):195-200. PubMed ID: 2982980
[TBL] [Abstract][Full Text] [Related]
66. Evidence for endogenous dopaminergic control of mineralocorticoids secretion in normal subjects and in patients with hyperaldosteronism.
Shimizu Y; Hanew K; Sato S; Sasaki A; Murakami O; Yoshinaga K
Tohoku J Exp Med; 1984 Sep; 144(1):33-42. PubMed ID: 6506061
[TBL] [Abstract][Full Text] [Related]
67. Adrenal glomerulosa function in patients with dexamethasone-suppressible hyperaldosteronism.
Oberfield SE; Levine LS; Stoner E; Chow D; Rauh W; Greig F; Lee SM; Lightner E; Witte M; New MI
J Clin Endocrinol Metab; 1981 Jul; 53(1):158-64. PubMed ID: 7016891
[TBL] [Abstract][Full Text] [Related]
68. The broad phenotypic spectrum of 17α-hydroxylase/17,20-lyase (CYP17A1) deficiency: a case series.
Sun M; Mueller JW; Gilligan LC; Taylor AE; Shaheen F; Noczyńska A; T'Sjoen G; Denvir L; Shenoy S; Fulton P; Cheetham TD; Gleeson H; Rahman M; Krone NP; Taylor NF; Shackleton CHL; Arlt W; Idkowiak J
Eur J Endocrinol; 2021 Oct; 185(5):729-741. PubMed ID: 34524979
[TBL] [Abstract][Full Text] [Related]
69. Suppression and stimulation of mineralocorticoid hormones (MCH) in the simple virilizing form of congenital adrenal hyperplasia (CAH) evaluated by the quantitation in adrenal venous blood.
Wajchenberg BL; Biglieri EG; Okada H; Malerbi DA; Achando SS; Kater CE
J Steroid Biochem; 1983 Jul; 19(1B):655-61. PubMed ID: 6350722
[TBL] [Abstract][Full Text] [Related]
70. New studies of the 11 beta-hydroxylase and 18-hydroxylase enzymes in the hypertensive form of congenital adrenal hyperplasia.
Levine LS; Rauh W; Gottesdiener K; Chow D; Gunczler P; Rapaport R; Pang S; Schneider B; New MI
J Clin Endocrinol Metab; 1980 Feb; 50(2):258-63. PubMed ID: 6243663
[TBL] [Abstract][Full Text] [Related]
71. Etomidate: a selective adrenocortical 11 beta-hydroxylase inhibitor.
Dörr HG; Kuhnle U; Holthausen H; Bidlingmaier F; Knorr D
Klin Wochenschr; 1984 Nov; 62(21):1011-3. PubMed ID: 6096625
[TBL] [Abstract][Full Text] [Related]
72. An adrenocortical tumor secreting weak mineralocorticoids.
Makino K; Yasuda K; Okuyama M; Ojima M; Sasano N; Miura K
Endocrinol Jpn; 1987 Feb; 34(1):65-72. PubMed ID: 3608914
[TBL] [Abstract][Full Text] [Related]
73. Hypoaldosteronism accompanied by normal or elevated mineralocorticosteroid pathway steroid: a marker of adrenal carcinoma.
Aupetit-Faisant B; Battaglia C; Zenatti M; Emeric-Blanchouin N; Legrand JC
J Clin Endocrinol Metab; 1993 Jan; 76(1):38-43. PubMed ID: 8421100
[TBL] [Abstract][Full Text] [Related]
74. Increased excretion of 18-hydroxycorticosterone in patients with adrenal adenomas and hypertension.
Vecsei P; Abdelhamid S; Haack D; Lichtwald K; Lewicka S; von Mittelstädt G
Clin Exp Hypertens A; 1982; 4(9-10):1759-70. PubMed ID: 6291815
[TBL] [Abstract][Full Text] [Related]
75. Unusual low plasma renin hypertension in a child.
Sann L; Revol A; Zachmann M; Legrand JC; Bethenod M
J Clin Endocrinol Metab; 1976 Aug; 43(2):265-71. PubMed ID: 181394
[TBL] [Abstract][Full Text] [Related]
76. Stimulation and suppression of the mineralocorticoid hormones in normal subjects and adrenocortical disorders.
Kater CE; Biglieri EG; Brust N; Chang B; Hirai J; Irony I
Endocr Rev; 1989 May; 10(2):149-64. PubMed ID: 2666117
[TBL] [Abstract][Full Text] [Related]
77. Effects of ACTH on steroid metabolism.
Messerli FH; Nowaczynski W; Honda M; Genest J; Kuchel O
J Clin Endocrinol Metab; 1976 Jun; 42(6):1074-80. PubMed ID: 180044
[TBL] [Abstract][Full Text] [Related]
78. Regulation of 18-hydroxydeoxycorticosterone in the rat.
Tan SY; Mulrow PJ
Endocrinology; 1978 Apr; 102(4):1113-7. PubMed ID: 217614
[TBL] [Abstract][Full Text] [Related]
79. Late-onset 21-hydroxylase deficiency: reliable diagnosis by steroid analysis of random urine collections.
Shackleton CH; Irias J; McDonald C; Imperato-McGinley J
Steroids; 1986; 48(3-4):239-50. PubMed ID: 3502202
[TBL] [Abstract][Full Text] [Related]
80. Determination of steroid profiles in healthy and diseased states: identification and quantitation of a block of 17 alpha-hydroxylase.
Fennessey PV; Marsh PG; Orr ER; Burnstein P; Betz G
Clin Chim Acta; 1983 Mar; 129(1):3-11. PubMed ID: 6303630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
